Arthur Nwaubani
Neurology with Special Qualifications in Child Neurology · Leesburg, FLNPI 1679748107
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,411 of the $5,014 with a category attached, or 68.0%. 25 manufacturers reported payments, led by Livanova USA, Inc. at 36.9% of the total. Reporting peaked in 2019 at $2,767 and has fallen 92.1% since, to $218 in 2025.
Across 130 payments — averaging $38.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$2K
- Supernus Pharmaceuticals, Inc.$891
- Medtronic$477
- Neurelis, Inc.$356
- UCB, Inc.$348
- Aquestive Therapeutics, Inc.$195
- plus $896 from 19 others
What the payments were for
- Speaking & faculty fees$50010%
- Travel & lodging$1,07221%
- Food & beverage$3,41168%
- Education$311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 23 | $1,852 |
| Supernus Pharmaceuticals, Inc. | 21 | $891 |
| Medtronic | 4 | $477 |
| Neurelis, Inc. | 18 | $356 |
| UCB, Inc. | 15 | $348 |
| Aquestive Therapeutics, Inc. | 12 | $195 |
| Sunovion Pharmaceuticals Inc. | 8 | $183 |
| Tris Pharma Inc | 1 | $122 |
| SK Life Science, Inc. | 4 | $95 |
| Sumitomo Pharma America, Inc. | 3 | $83 |
| Novartis | 2 | $46 |
| Ironshore Pharmaceuticals Inc. | 2 | $44 |
| Collegium Pharmaceutical, Inc. | 2 | $43 |
| Greenwich Biosciences, Inc. | 2 | $35 |
| Travere Therapeutics, Inc. | 3 | $31 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Eisai Inc. | 1 | $25 |
| Immedica Pharma US, Inc. | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Aprecia Pharmaceuticals, LLC | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Cranial Technologies, Inc | 1 | $21 |
| Aucta Pharmaceuticals, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,414
- OXTELLAR XR$625
- INTERSTIM$317
- Dyanavel XR$122
How this compares
$5,014 in reported general payments places this provider in the 60th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
See all neurology with special qualifications in child neurology providers in Florida →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 11 | $84 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Leesburg
- Paul WinnerWest Palm Beach$624K
- Omer Abdul HamidOrlando$283K
- Natalie GillsonFort Myers$250K
- Trevor ResnickMiami$230K
- Migvis MonduyMiami$188K
- Elza VasconcellosMiami$170K
- Ronald DavisWinter Park$154K
- Ian MillerMiami$104K
- Michael HammerSaint Petersburg$100K
- Matt LallasMiami$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.